Although some patients were assumed to discontinue anemia treatment after the recovery of Hb concentration to the target level, the notably high proportion of patients without any treatment suggests the need for further investigation regarding barriers for treatment continuation to maintain a stable Hb concentration in patients with NDD-CKD. This evidence concerns the gene GSTM1 and anemia (phenotype).